MedTrace Logo

Pre-approval Expanded Access of Retatrutide (LY3437943)

NCT07629401 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-08-06

No results posted yet for this study

Summary

Provide pre-approval single-patient expanded access of retatrutide (LY3437943), an investigational GLP-1/GIP/glucagon triple receptor agonist being studied for chronic weight management, for adults with severe obesity (body mass index \[BMI\] greater than or equal to \[≥\]35 kilogram per square meter \[kg/m²\] and at least two serious or life-threatening obesity-related complications who are refractory to the best approved therapy and are unable to participate in an ongoing clinical trial of retatrutide or a comparable investigational medicine.

Conditions

  • Obesity
  • Obesity-related Complications

Interventions

DRUG

Retatrutide

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07629401 on ClinicalTrials.gov